Group items tagged

This award is in memory of Linda Arenth, an active ONS and ONCC member who served as the Johns Hopkins Cancer Center's first director of nursing.  She started what is now a nationally known system to assign nursing services for different categories of cancer patients.  This award recognizes and supports excellence in both cancer nursing management and administration.

The Leukemia & Lymphoma Society (LLS) Career Development Program (CDP) offers you the opportunity to take part in basic, clinical or translational research to help understand and treat hematologic malignancies and relevant premalignant conditions. We'll award you with a stipend so you can devote yourself to research. We offer career development awards for various stages of your research career. Please verify in our Program Category Specific Eligibility Criteria table which award is appropriate for your level of experience and Apply to that category of award.

The goal of the Office of Science Graduate Student Research (SCGSR) program is to prepare graduate students for science, technology, engineering, or mathematics (STEM) careers critically important to the DOE Office of Science mission, by providing graduate thesis research opportunities at DOE laboratories.  The SCGSR program provides supplemental awards to outstanding U.S. graduate students to pursue part of their graduate thesis research at a DOE laboratory in areas that address scientific challenges central to the Office of Science mission. The research opportunity is expected to advance the graduate students' overall doctoral thesis while providing access to the expertise, resources, and capabilities available at the DOE laboratories.

We're looking for big thinkers to create innovations and solutions improving the daily lives of people facing cancer.

The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field. Awards are made to institutions for support of the Damon Runyon-Rachleff Innovation Investigators. All awards are approved by the Board of Directors of the Damon Runyon Cancer Research Foundation acting upon the recommendation of the Innovation Award Committee.

The Lila and Murray Gruber Memorial Cancer Research Award is one of the largest and most prestigious medical awards. The cash award of $10,000 will be made in recognition of the investigator's lifetime achievements in the field of cancer research. The award has been made possible by a gift from Murray Gruber in memory of his wife. Its purpose is to encourage participation in cancer research and to provide a forum for the enrichment of knowledge of dermatologists in this important scientific field. At the discretion of the task force, the award may be divided between two worthy nominees.

The AACR and its Chemistry in Cancer Research Working Group established this award in 2007 to recognize the importance of chemistry to advancements in cancer research. The award will be given for outstanding, novel and significant chemistry research, which has led to important contributions to the fields of basic cancer research, translational cancer research, cancer diagnosis, the prevention of cancer or the treatment of patients with cancer. Such research may include, but is not limited to, drug discovery and design; structural biology; proteomics, metabolomics and biological mass spectrometry; chemical aspects of carcinogenesis; imaging agents and radiotherapeutics; and chemical biology.

To stimulate research that will generate new knowledge of the effects of the US healthcare system structure and the role of insurance on both access to and outcomes of cancer screening, early detection and treatment services. Studies investigating how one or more factors impacting access and outcomes interact - such as insurance status, costs, capacity, personal characteristics, provider characteristics, components of the healthcare delivery system and other known factors - are encouraged.

The ASGE Endoscopic Research Awards are offered to physicians for projects in basic, translational and clinical endoscopic research. ASGE is particularly interested in endoscopic research pertaining to Barrett's esophagus, capsule endoscopy, colorectal cancer, endoscopic issues specific to under-represented minorities (defined as women and individuals of diverse ethnic/cultural backgrounds), controlled trials in endoscopic ultrasound, endoscopic retrograde cholangiopancreatography (ERCP), endoscopic optical recognition techniques, measuring quality in endoscopy, NOTES™, and novel endoscopic treatments for obesity. 

Rally funds research in the following areas: -Under-studied cancer types -Innovative approaches to childhood cancer research which could lead to advanced studies or clinical trials -Studies that are likely to lead to a clinical trial, personalized, alternative, or integrated research proposals -Quality of life and survivorship research proposals

LUNGevity's Career Development Awards for Translational Research program was created to support future research leaders who will keep the field of lung cancer research vibrant with new ideas. Applicants must be within the first five years of their faculty appointment. The Career Development Awards are mentored awards; a mentoring plan is part of the required submission. Projects that will be funded in 2018 are expected to have a direct impact on the early detection of lung cancer or on the outcomes of lung cancer, or to provide a clear conceptual or experimental foundation for the future development of methods for early detection and/or individualized treatment, including through targeted therapy and immunotherapy. Career Development Awards may be for a maximum of $300,000: $100,000 per year for 3 years

Elsa Uhinck Pardee was born on a farm south of Cleveland, Ohio, on November 7, 1884, and received her elementary education in a one-room school. She married James T. Pardee in 1914. A college classmate of Herbert H. Dow, Mr. Pardee was a founder and board member of the Dow Chemical Company. Before her death from breast cancer in 1944 at the age of 59, Elsa directed that $1 million in Dow stock be devoted to the "control and cure of cancer." The Elsa U. Pardee Foundation was formed in memory of Elsa by the family she left behind.

Applications will be accepted for a broad range of melanoma research projects involving basic science, clinical trials, etc. 1. An adequate discussion of biostatistics is required, including but not limited to specification of numbers of cell lines, laboratory animals, or patients to be treated in the studies. 2. Plans for adjustment for multiple looks should be presented, particularly in regards to clinical endpoints and evaluation of multiple biomarkers.